Clinical Trials
8 trialsNCT02954991 2024-04-22
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT02282358 2024-03-08
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT02805660 2021-04-06
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mirati Therapeutics Inc.
Phase 1/2 Terminated
NCT00358982 2015-07-03
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00374296 2015-07-01
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00543582 2015-07-01
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00666497 2015-05-08
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT00511576 2015-01-08
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Phase 1 Terminated